Pyxis Oncology (PYXS)
(Real Time Quote from BATS)
$1.11 USD
+0.01 (0.91%)
Updated Aug 5, 2025 09:48 AM ET
3-Hold of 5 3
F Value F Growth D Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
PYXS 1.11 +0.01(0.91%)
Will PYXS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for PYXS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PYXS
Zacks Industry Outlook Highlights Aurinia Pharmaceuticals, Heron Therapeutics, Esperion Therapeutics, Pyxis Oncology and Plus Therapeutics
5 Small Drug Stocks to Buy as Tariff-Related Uncertainty Looms
PYXS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Top Cancer Stocks to Buy to Boost Your Portfolio's Health
Biotech Stock Roundup: SAGE, INCY Suffer Setbacks, JAZZ Wins Oncology Drug Approval & More
Other News for PYXS
Crescent Biopharma appoints Jan Pinkas as CSO
Pyxis Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | PYXS Stock News
Pyxis Oncology Elects New Directors at Annual Meeting
Pyxis Oncology Reports Increased Losses Amidst Ongoing R&D Investments
Promising Developments and Risk-Reward Profile Justify Buy Rating for Pyxis Oncology